Lexeo Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
LXEO$3.06-2.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss (unaudited)
Condensed Statements of Operations and Comprehensive Loss
(Unaudited, in thousands, except share and per share amounts)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating expenses | ||
| Research and development | $15,703 | $17,171 |
| General and administrative | 6,630 | 16,634 |
| Total operating expenses | 22,333 | 33,805 |
| Operating loss | (22,333) | (33,805) |
| Other income and expense | ||
| Other expense, net | (1) | (4) |
| Interest expense | (17) | (28) |
| Interest income | 2,113 | 1,193 |
| (Amortization of premium) accretion of discount on investments in U.S. Treasury securities, net | 42 | (12) |
| Total other income and expense | 2,137 | 1,149 |
| Loss from operations before income taxes | (20,196) | (32,656) |
| Income taxes | - | - |
| Net loss | $(20,196) | $(32,656) |
| Other comprehensive gain (loss) | ||
| Net unrealized gain (loss) on investments | (330) | 49 |
| Total other comprehensive gain (loss) | (330) | 49 |
| Comprehensive loss | $(20,526) | $(32,607) |
| Net loss per common share, basic and diluted | $(0.25) | $(0.99) |
| Weighted-average number of shares outstanding used in computation of net loss per common share, basic and diluted | 81,183,812 | 33,113,991 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.